By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
The physiology of satiety: a conversation between gut and brain
The physiology of satiety is not a single moment of “that’s enough.” It is a carefully orchestrated biological process. Dozens of hormones from the stomach, intestine, pancreas and fat tissue are in constant conversation with the brain, mainly with the hypothalamus and the brainstem. Understanding that conversation is the foundation of modern obesity treatment, from GLP-1 medications to bariatric surgery.
This article draws on two reviews: a review of the role of somatostatin in satiety and obesity, and a review of biased signaling at the MC4R receptor. It also brings in key studies and updates through October 2026.
Why the satiety mechanism matters
Obesity is one of the world’s biggest health problems. According to World Health Organization data, 1.1 billion people were living with obesity in 2024, one in every seven people, including 940 million adults. And the body’s energy balance is remarkably delicate: according to the review, a gap of less than 0.5% between intake and expenditure is enough to cause weight gain over time.
That is why the body runs such a complex control system. As early as 1953, Gordon Kennedy proposed that signals in the blood report the size of the body’s fat stores to the brain. Since then, it has become clear that the hypothalamus is the main control center, but it is far from the only player.
Satiation and satiety: two different concepts
Satiation is the process that brings a meal to an end. Satiety, by contrast, is the feeling of fullness that lasts after the meal. Satiety influences when the next meal happens and how large it is. In other words, good satiety reduces the urge to snack over time.
Most of this information reaches the brainstem through the vagus nerve. The signals come from stretching of the stomach, chemical stimulation of the intestinal lining and the release of hormones. Put simply, satiety starts in the belly and ends in the head.
The gut-brain axis and the hypothalamus
Signals from the body reach the brain by two routes. The first is the bloodstream: hormones travel to areas of the brain where the blood-brain barrier is only partial. The second is neural: vagal fibers carry information from the gut to the brainstem. From there, projections run to the hypothalamus, where meal-related signals are integrated with signals about the body’s fat stores.
The brain’s reward system is also at work, driving the pleasure we get from tasty food. It is part of the explanation for “food noise,” those intrusive, persistent thoughts about food. Lesion studies in animals revealed the roles of different regions of the hypothalamus. For example, damage to the ventromedial area causes hyperphagia (excessive eating) and obesity.
The arcuate nucleus: hunger versus satiety
The arcuate nucleus is the heart of the control system. Because the blood-brain barrier does not fully shield it, it can directly “taste” the hormones circulating in the blood. Two populations of neurons work against each other here.
Hunger neurons produce NPY and AgRP. In an experiment in mice, activating AgRP neurons alone triggered vigorous eating within minutes, with no training required. Satiety neurons, on the other hand, produce POMC and CART. POMC gives rise to the hormone α-MSH, which activates the MC4R receptor and produces satiety.
Hormones from the body tip the balance. Leptin and insulin activate the satiety neurons and inhibit the hunger neurons. Ghrelin works in the opposite direction.
The physiology of satiety: gut and pancreatic hormones
Most gut hormones reduce food intake. The notable exception is ghrelin. These are the main players:
- CCK: released from the duodenum; together with stomach stretch, it is a key signal for ending a meal.
- GLP-1: released from L cells in the intestine. In a study in humans, a GLP-1 infusion reduced food intake by up to 35%. This is the basis for how GLP-1 medications act in the brain.
- PYY and oxyntomodulin: also produced by intestinal cells, and both reduce food intake.
- Insulin and amylin: produced by beta cells in the pancreas. I have written separately about how amylin works.
- Ghrelin: released from the stomach, it is the main hormone that increases appetite.
Leptin and leptin resistance
Fat cells secrete leptin, and its blood level reflects how much fat the body carries. During fasting, leptin levels fall and appetite rises. The paradox is that in obesity, leptin levels are actually high. This is leptin resistance: the signal is there, but the brain does not “hear” it.
The final checkpoint in the physiology of satiety: MC4R
The melanocortin 4 receptor (MC4R) sits at the end of the regulatory chain. Mutations that knock out its function cause severe obesity starting in childhood. Conversely, mutations that increase its activity are associated with leanness.
For years, researchers thought of this receptor as a simple switch. We now know that it activates several pathways inside the cell, each with a different role. This phenomenon is called biased signaling. For example, a UK Biobank study characterized 61 MC4R variants in half a million people. Recruitment of the protein β-arrestin explained 88% of the variance in the association between the variants and BMI. In addition, gain-of-function variants were linked to a lower risk of obesity, type 2 diabetes and coronary heart disease.
From insight to medication: setmelanotide
Older drugs that activated MC4R suppressed appetite, but they raised blood pressure and heart rate and caused other side effects. Setmelanotide, by contrast, suppressed appetite without significant cardiac side effects. According to the review, it is strongly biased toward the satiety pathway. The FDA first approved it in 2020 for rare genetic forms of obesity.
In March 2026, the FDA also approved setmelanotide for acquired hypothalamic obesity, from age 4. In the TRANSCEND trial, BMI fell by 15.8% with the drug, compared with a 2.6% increase on placebo. There is a notable Israeli contribution here, too: in 2021, a team from the Weizmann Institute and the Hebrew University, working with colleagues in London, solved the structure of the active receptor bound to setmelanotide.
Somatostatin: the two-faced hormone
Somatostatin was discovered in 1973 as a peptide that inhibits the release of growth hormone. It has since become clear that it acts both in the brain and in the digestive system. In the gut, it promotes satiety, mainly by slowing stomach emptying. At the same time, it inhibits the release of CCK and GLP-1, so it may also weaken satiety. In the brain, the picture is reversed: injecting it into the brain’s ventricles increased eating in rodents.
The somatostatin analog octreotide has been tested in hypothalamic obesity, a complication of brain tumors. In a randomized trial in 18 children, weight rose by only 1.6 kg with the drug, compared with 9.1 kg on placebo, over six months. In adults with common obesity, however, the effect is minimal.
Stress, reward and the physiology of satiety
Stress affects eating in both directions. Glucocorticoids, the stress hormones, increase appetite, and under chronic stress they also raise ghrelin. In addition, the protein BDNF acts downstream of MC4R and suppresses eating; when it is lacking, hyperphagia and obesity develop. These mechanisms explain why the brain asks for food even when we are not hungry. You can find practical tools in my guide to stress relief.
The power of gut hormones is also evident after bariatric surgery. After sleeve gastrectomy, levels of PYY and GLP-1 rise and affect appetite. In effect, surgery and medication act on the same hormonal system.
The bottom line on the physiology of satiety
Satiety is the product of an ongoing conversation between the gut, the pancreas, fat tissue and the brain. The arcuate nucleus weighs up the signals and decides between hunger neurons and satiety neurons. That decision passes through MC4R, a receptor far more complex than an on-off switch. The better we understand the physiology of satiety, the better we can match each patient with the right treatment: medication, surgery or a combination. I have also written about making that choice in my guide to holistic obesity treatment.
The information in this article is general and does not replace personal medical advice.
References
Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity
MC4R biased signalling and the conformational basis of biological function selections
AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training
Glucagon-like peptide-1: a potent regulator of food intake in humans
Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity
Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling
Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial
